Quality of medicines in Portugal: a retrospective review of medicine recalls ( ) Ana Teresa Reis Bruna Berardo Rui Loureiro

Similar documents
EUROPEAN COMMISSION DIRECTORATE-GENERAL III INDUSTRY Industrial affairs III: Consumer goods industries Pharmaceuticals and Cosmetics

Principals and dosage forms of pharmaceutics

List of nationally authorised medicinal products

List of nationally authorised medicinal products

300 3PORTUGUESE 65M GLOBAL WHO WE ARE WE OFFER PORTUGUESE

GUIDELINE ON THE CATEGORISATION OF EXTENSION APPLICATIONS (EA) versus VARIATIONS APPLICATIONS (V) OCTOBER 2003

EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL VOLUME 2C. Guidelines. Medicinal products for human use

Legal Supplement Part B Vol. 57, No. 6 18th January, NOTIFICATION NOTICE OF APPROVAL IN RESPECT OF NEW DRUGS

Assessment of Human Pharmaceutical Products Registered in Kenya by Route of Administration and Type of Dosage Form

THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES

<1151> Pharmaceutical Dosage Forms and <1152> Animal Drugs for Use in Animal Feeds

Systemic and inhaled fluoroquinolones: risk of aortic aneurysm and dissection

Please note that this draft Annex I will be updated to amend information on concerned products/mahs

Medication Administration. By: Carolyn McCune RN, BSN, MSN, CRNP

Decentralised Procedure. Public Assessment Report. Memantin AbZ 10 mg/20 mg Filmtabletten ; Starterpack

MEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS. PHM154A September Anand Gijare Project Analyst ISBN:

PHARMACEUTICS I صيدالنيات 1 UNIT 1 INTRODUCTION

Award of Contracts without Competition December 2013

For External Use Only. Should neither be swallowed. Nor injected

Marketing authorisations granted in September 2012

INFORMATION TOPIC: II-5 OR DEMONSTRATION: II-5. DOSAGE, MEASUREMENTS, AND DRUG FORMS (Lesson Title) OBJECTIVES THE STUDENT WILL BE ABLE TO:

Member State Marketing Authorisation Holder Invented Name Strength Pharmaceutical Route of administration

Palliative Coverage Drug Benefit Supplement

EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL VOLUME 2C. Guidelines. Medicinal products for human use

Suspected Defective Product Report

DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

WITH APPLICATIONS TO : ; : GENERAL AND SPECIALTY AREAS

(Adopted by the Committee of Ministers on 19 January 2011 at the 1103rd meeting of the Ministers Deputies)

US pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health

OVERVIEW OF COMMENTS RECEIVED ON COMMUNITY HERBAL MONOGRAPH ON HAMAMELIS VIRGINIANA L., FOLIUM (EMEA/HMPC/114586/2008)

Update on the revision of the new package leaflet (PL) template. An agency of the European Union

Cooperation between HALMED and GMP Inspectorate in supervision of manufacturers: Croatia s experience so far

INFORMATION TOPIC: II-5 OR DEMONSTRATION: II-5. DOSAGE, MEASUREMENTS, AND DRUG FORMS (Lesson Title) OBJECTIVES THE STUDENT WILL BE ABLE TO:

Introduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Package leaflet: Information for the User Clarityn 10 mg tablets Loratadine

What's Important to Consider When Developing a Complex Generic Drug? September 5, 2018


Frequently asked questions

Routes of drug administration

67 Years of Leadership in Pharmacy. A Journey of Continuous Improvement

905 UNIFORMITY OF DOSAGE UNITS

List of nationally authorised medicinal products

Free Trial Future Generics Database

Completion of the development of a formulation: Requirements for compliance check vs. requirements for Marketing Authorisation

PRAC recommendations on signals

Public Assessment Report. Scientific discussion. Desloratadine Lek 5 mg film-coated tablets. (Desloratadine) DK/H/2041/001/DC.

Disclosure. Objectives. Objectives. Introduction. Introduction. Non-Sterile Compounding/Calculations

LIQUID PREPARATIONS FOR ORAL USE. Final text for addition to The International Pharmacopoeia (November 2007)

Opinion 8 January 2014

Changing practice to support service delivery

PRAC recommendations on signals

ANNEX I LIST OF THE NAMES OF THE MEDICINAL PRODUCTS, MARKETING AUTHORISATION HOLDERS, PHARMACEUTICAL FORMS, STRENGTHS, ROUTE OF ADMINISTRATION,

European Medicines Agency decision

A Layperson s Guide to Pediatric Formulation Development

International Pharmaceutical Aerosol Consortium on Regulation and Science

Artemether 20mg/lumefantrine 120mg WHOPAR part 5 12/2011 Dispersible tablets (Novartis Pharma AG), MA069 LABELLING. Page 1 of 6

United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS DECENTRALISED PROCEDURE

EU PSUR Work Sharing Summary Assessment Report AFLAMIN (aceclofenac) HU/H/PSUR/0030/002 HU

REGULATORY UPDATES: APPROVAL, DENIALS AND AGREEMENTS REGULATORY UPDATES: APPROVAL, (CONTINUED)... 38

Allergan s Blephamide (sulfacetamide/prednisolone ophthalmic ointment) 10%/0.2%, 3.5Gm tube

T Pharmaceutics-I (Dispensing Pharmacy)

Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles

Medication errors. Impact of medication error guidance and regulation on drug-device combination products. June 2017 Dan Wozinski

Draft Guideline on Pharmaceutical Development of Medicines for Paediatric Use. C. Nopitsch-Mai London 1

Public Assessment Report. Scientific discussion. Elisox 50 microgram/actuation, nasal spray, suspension. (mometasone furoate) NL/H/2672/001/DC

Europe Ginseng Market Report 2016

EXCIPIENTS FOR PHARMACEUTICALS

BRITISH PHARMACOPOEIA COMMISSION EXPERT ADVISORY GROUP: MEDICINAL CHEMICALS 3 SUMMARY MINUTES

Amoxicillin 40 mg Clavulanic acid 10 mg. Clavulanic acid 10 mg. Clavulanic acid 10 mg. Clavulanic acid 10 mg

Blanka Hirschlerová. EDQM CEP conference Prague, Czech Republic

IMDG CODE Poison Treatment Chest

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on. 18/08/2017 SmPC and PL. 24/05/2017 SmPC, Annex II, Labelling

Thomas Karlsson & Esa Österberg National Research and Development Centre for Welfare and Health Alcohol and Drug Research Group P.O.

CONTRACT UPDATE July 20, 2012

COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global

Summary Public Assessment Report. Generics. Etoricoxib Aurobindo. 30 mg, 60 mg, 90 mg, 120 mg Film-coated tablet (Etoricoxib) PT/H/1603/ /DC

IMDG CODE Poison Treatment Chest

List of nationally authorised medicinal products

Information for Vermont Prescribers of Prescription Drugs

Annex I. Article 107i of Directive 2001/83/EC. Procedure number: EMEA/H/A-107i/ March 2013 EMA/147828/2013 Patient Health Protection

Allopathic Medicines and Types

MEDICINES CONTROL AGENCY GUIDELINE FOR REGISTRATION OF FOOD/NUTRITIONAL/DIETARY SUPPLEMENTS IN THE GAMBIA

Lessons learned on the review of the labelling of pandemic vaccines

EUROPEAN AEROSOL PRODUCTION

Summary Public Assessment Report. Generics. Amiodarona Aurobindo. 200 mg, Tablets. (Amiodarone hydrochloride) PT/H/1444/001/DC

CHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW...

CHAPTER ONE: EXECUTIVE SUMMARY

Information for Vermont Prescribers of Prescription Drugs

CHAPTER ONE: EXECUTIVE SUMMARY

List of nationally authorised medicinal products

John Ansell President, John Ansell Consultancy Thame, UK

PUBLIC ASSESSMENT REPORT Scientific Discussion

INTERNATIONAL PHARMACOPOEIA MONOGRAPH ON LIQUID PREPARATIONS FOR ORAL USE

London, 24 January 2000 EMEA/1952/00

UNIT I EVOLUTION OF THE PHARMACY

MEDICINES SHORTAGES PGEU GPUE. John Chave - Secretary general. Pharmaceutical Group of European Union Groupement Pharmaceutique de l Union Européenne

ANNEX I NAME, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ANIMAL SPECIES, ROUTES OF ADMINISTRATION, AND MARKETING AUTHORISATION HOLDER

Recommended comparator products: Medicines for HIV/AIDS and related diseases

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Transcription:

Quality of medicines in Portugal: a retrospective review of medicine recalls (2005-2015) Ana Teresa Reis Bruna Berardo Rui Loureiro

Introduction Human medicines Cosmetics Veterinary medicines Medical devices Herbal and homeopathic medicines Other health products

Introduction Human medicines Cosmetics Veterinary medicines Medical devices Herbal and homeopathic medicines Other health products

Introduction INFARMED Alerts Quality Alerts Safety Alerts Medicinal Products Other Health Products Human Medicine Recall Alerts

Materials/Methods o INFARMED website Quality Alerts 2005-2015 o Excel database File number Issuing date Drug name and Dosage Generic Comercially available MA Status MAH No. batches affected Expiry Date Shelf Life Time on the Market Pharmaceutical Dosage Form Quality Defect Issuing Agency Voluntary/Mandatory recall Notes

Materials/Methods o Item Time on the Market Expiry Date Shelf Life = Production Date Alert Issuing Date Production Date = Time on the market 0-6 months 7-12 months 13-18 months 19-24 months 25-30 months 31-36 months > 36 months

Materials/Methods o Item Pharmaceutical Dosage Form Oral Solids Tablets Capsules Lozenges Powders and/or granules for oral suspension/oral solution Liquids and Semi-solids Injectables Creams Ointments Gels Cutaneous solutions Transdermal systems Eye drops, eye ointments Powders for inhalation Pressurized inhalation solutions Oral suspensions and solutions Syrups Oral gels Oral drops Mouth solutions Solutions for gargling Ovules Vaginal ointments Rectal suppositories Rectal ointments

Total Alerts Issued (2005-2015) n = 1115 60 Total Alerts other Health Products Total Medicine Alerts Medicine Recall Alerts Other Medicine Alerts 617 498 338 160 Total Alerts other Health Products Total Medicine Alerts Medicine Recall Alerts Other Medicine Alerts

Frequency Total Medicine Quality Alerts / Total Medicine Recalls 80 70 70 68 60 57 50 40 30 20 34 26 24 19 49 31 27 36 32 40 34 45 46 47 29 33 30 35 24 10 0 YEAR MEDICINES QUALITY ALERTS MEDICINE RECALLS

Frequency Total Medicine Quality Alerts (2005-2015) 80 70 60 70 68 57 50 40 30 47 46 45 40 36 34 31 24 20 10 0 YEAR

Frequency Total Medicine Quality Alerts (2005-2015) 80 70 60 70 68 57 50 40 30 47 46 45 40 36 34 31 24 20 10 0 YEAR

Frequency Total Medicine Quality Alerts / Total Medicine Recalls 80 70 70 68 60 57 50 40 30 20 34 26 24 19 49 31 27 36 32 40 34 45 46 47 29 33 30 35 24 10 0 YEAR MEDICINES QUALITY ALERTS MEDICINE RECALLS

Alerts Issued 1115 quality alerts were issued between 2005 and 2015 Production No. Medicine Quality Alerts issued Regulatory agencies awareness Pharmaceutical Industries awareness

No. of Recalls per Marketing Authorisation Holder MAH No. Recalls Sandoz 15 Generis 13 B. Braun Labesfal GlaxoSmithKline Janssen 12 Baxter 10 Sanofi Teva Pharma 9 Laboratórios Basi Mylan Ratiopharm Roche Schering Plough Farma 8 MAH Grünenthal Jaba Pfizer Novartis Wynn Actavis Alter Bristol-Myers Hospira Octapharma Pierre Fabre ToLife UCB Pharma No. Recalls 7 6 5 MAH Bayer Laboratórios Azevedos Pentafarma Ranbaxy Portugal Alexion Europe SAS Almirall Angelini Bluefish Farmacoquímica Baldacci Ferring Portuguesa Gilead Sciences Laboratório Medinfar Lundbeck Portugal Mallinckrodt Medical BV Tecnimede No. Recalls 4 3

No. Alerts issued Alerts Issued 300 294 200 100 0 Infarmed 6 UK 6 Spain 6 France 5 Germany 4 EMA 4 Italy 4 Denmark 9 Other

No. of defects Quality Defect Origin 237 200 100 45 46 0 Pharmaceutical Form Primary Packaging Secondary Packaging 1 4 3 2 Packaging Regulatory Affairs Other N/A

Affected Medicinal Products by Pharmaceutical Form 36% 45% Oral Solids Liquids and Semi-solids Injectables 19%

Recall Causes / Type o Product recall causes: 1. Pharmaceutical Dosage Form 2. Packaging problems o Pharmaceutical Dosage Form 36 % Injectables 45 % Oral Solids Pharmaceutical Industry concern with product s quality 87% (338) Voluntary recalls Efficient detection of quality issues

Number of Batches 29 1 batch 2 batches 3 batches 4 batches All product batches 78 158 26 47

Time on the Market 31-36 months 7% > 36 months 7% 0-6 months 17% 25-30 months 8% 19-24 months 18% 7-12 months 21% 13-18 months 22%

AUTHORS Ana Teresa Reis Bruna Berardo Rui Loureiro o QUESTIONS?

THANK YOU!